---
layout: post
title: FDA approves Ocaliva for PBC
date: 2016-06-14 10:00:00
---

![](/assets/images/fda-approves-ocaliva-for-pbc.png)

[**FDA Approves Ocaliva, New Drug for Primary Biliary Cirrhosis (PBC)**](https://www.hepmag.com/article/fda-approves-ocaliva-new-drug-primary-biliary-cirrhosis-pbc)

The U.S. Food and Drug Administration (FDA) has approved Intercept Pharmaceuticals' Ocaliva (obeticholic acid) to treat primary biliary cholangitis, previously known as primary biliary cirrhosis ( PBC), Fierce Biotech reports. The drug is approved for use in combination with ursodeoxycholic acid (UDCA) in adults who have responded inadequately to that drug or as a monotherapy in adults who cannot tolerate UDCA.

[**FDA approves Ocaliva for PBC - a rare chronic liver disease.pdf**](https://jumpshare.com/v/77Bc8up8PMhc6kdVTyLi)